US Patent

US10428063 — 4H-pyrrolo[3,2-C]pyridin-4-one derivatives

Composition of Matter · Assigned to Bayer Pharma AG · Expires 2035-10-10 · 9y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of 4H-pyrrolo[3,2-C]pyridin-4-one derivatives, including Sevabertinib, and their production and use as pharmaceuticals.

USPTO Abstract

Compound of formula (I), processes for their production and their use as pharmaceuticals.

Drugs covered by this patent

sevabertinib (SEVABERTINIB)

Patent Metadata

Patent number: US10428063
Jurisdiction: US
Classification: Composition of Matter
Expires: 2035-10-10
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Bayer Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.